## HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Sunitinib	
INITIATION – RCC Re-assessment required after 4 months Prerequisites (tick boxes where appropriate)	
The patient has metastatic renal cell carcinoma and The patient has not previously received funded sunitinib	
CONTINUATION – RCC Re-assessment required after 4 months Prerequisites (tick box where appropriate)  O No evidence of disease progression	
INITIATION – GIST Re-assessment required after 3 months Prerequisites (tick boxes where appropriate)	
The patient has unresectable or metastatic malignant gastrointed and  The patient's disease has progressed following treatment or Or The patient has documented treatment-limiting intolerance.	with imatinib
CONTINUATION – GIST Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)	
The patient has responded to treatment or has stable disease as follows:	s determined by Choi's modified CT response evaluation criteria as
The patient has had a complete response (disappearance or The patient has had a partial response (a decrease in siz (HU) of 15% or more on CT and no new lesions and no or	e of 10% or more or decrease in tumour density in Hounsfield Units byious progression of non-measurable disease)
and  The treatment remains appropriate and the patient is benefiting	from treatment
CONTINUATION – GIST pandemic circumstances Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)	
The patient has unresectable or metastatic malignant gastroints and The patient is clinically benefiting from treatment and continued and Sunitinib is to be discontinued at progression and The regular renewal requirements cannot be met due to COVID	treatment remains appropriate
The regular renewal requirements cannot be friet due to COVID	7 TO CONSTRAINTS ON THE HEARTH SECTOR

I confirm that the above details are correct:

Old 1 <del>c</del> d	

## HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:

Sunitinib - continued

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

